MRX-4: Final Phase II data

Final data from a double-blind, South African Phase II trial in 105 patients with allergic rhinitis showed that MRX-4 met the primary endpoint of safety vs. placebo. MRX-4 also met all secondary endpoints by significantly reducing symptoms of nasal congestion and frontal headaches, and significantly reducing eosinophils, IL-5, IL-13, eotaxin, MCP-1 and TNF alpha in nasal lavage fluid vs. placebo. MRX-4 was well tolerated, and treatment-emergent adverse events were similar between groups. Patients received twice-daily intranasal MRX-4 or placebo for 6 days followed by an intranasal dose of allergen on day 7. Data were presented at the European Academy of Allergy and Clinical Immunology meeting in London. ...